Management Principles Associated With Cytokine Release Syndrome

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• Chimeric antigen receptor (CAR) T-cell immunotherapy is an evolving treatment modality.
• CAR T-cell therapy is associated with significant adverse events, including cytokine release syndrome (CRS) and neurotoxicity.
• Effective management of these side effects is critical for patient safety and treatment success.

Purpose of the Study:

• To outline current recommendations and resources for nurses caring for patients with CRS.
• To emphasize the role of nursing in advocating for patients undergoing CAR T-cell therapy.
• To highlight the importance of nursing knowledge in managing CRS and neurotoxicity.

Main Methods:

• A literature search was conducted using keywords: cytokine release syndrome, neurotoxicity, CAR T, and adverse events.
• The search aimed to identify relevant recommendations and resources for nursing practice.

Main Results:

• Nursing is the first line of defense in monitoring patients receiving CAR T-cell therapy.
• Nursing expertise is vital for the prompt recognition of CRS and neurotoxicity symptoms.
• Adherence to updated standards and recommendations is necessary as CAR T-cell therapies advance.

Conclusions:

• Nurses play a pivotal role in improving patient outcomes through early identification and management of CRS and neurotoxicity.
• Continuous education and resource availability are essential for nurses to effectively advocate for and manage these patients.
• Further development of standards for managing CRS and neurotoxicity is anticipated with the progression of CAR T-cell research.